[Feasibility of apoptosis-imaging agent 99mTc-HYNIC-annexin V in early assessment of chemotherapeutic effect on tumor models]

Zhonghua Zhong Liu Za Zhi. 2008 Oct;30(10):737-40.
[Article in Chinese]

Abstract

Objective: To evaluate if 99mTc-HYNIC-annexin V may be used to detect the early chemotherapeutic effect and to determine the best timing for detecting apoptosis in vivo.

Methods: Annexin V was labeled with 99mTc using HYNIC as a bifunctional agent. Normal Kunming mice received inoculation of Ehrlich ascites cells into the right upper limb. After the tumor reached 1 cm in diameter, the mice were randomly divided into saline treatment group as control and cyclophosphamide (150 mg/kg injected intraperitoneally) treatment group. 99mTc-HYNIC-annexin V was injected intravenously at 1 h and 24 h after treatment. Region of interest technique (ROI) from the SPECT images taken at different time was used to get the ratio of tumor/limb in each group. TUNEL staining was used to detect apoptotic cells and the rates of positive stained cells were calculated.

Results: After treatment with saline, only little amount of the radiolabeled tracer could be seen in the tumor and showed weak image of the tumor. But after 24 h of treatment with cyclophosphamide, clear image on the tumor could be seen. 24 h after the treatment of cyclophosphamide, the ratio of tumor/limb was (6.27 +/- 0.24) which was much higher than that at 24 h after treatment with saline (2.36 +/- 0.18) and that at 1 h after cyclophosphamide treatment (4.00 +/- 0.38). At 24 h after cyclophosphamide treatment, TUNEL staining showed a significantly higher rate of apoptotic cells in the mice.

Conclusion: 99mTc-HYNIC-annexin V can be used as an apoptosis-imaging agent to detect and evaluate the early curative effect after chemotherapy. The effective detection of apoptotic response in tumor with 99mTc-HYNIC-annexin V requires a 24 h interval after chemotherapy. SPECT images can be obtained at 60 min after injection of the imaging agent. It suggests that 99mTc-HYNIC-annexin V may become a promising agent for apoptosis-imaging in clinical application.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Annexin A5* / pharmacokinetics
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Apoptosis* / drug effects
  • Carcinoma, Ehrlich Tumor / diagnostic imaging*
  • Carcinoma, Ehrlich Tumor / drug therapy
  • Carcinoma, Ehrlich Tumor / pathology
  • Cyclophosphamide / therapeutic use*
  • Male
  • Mice
  • Neoplasm Transplantation
  • Organotechnetium Compounds* / pharmacokinetics
  • Radiopharmaceuticals / pharmacokinetics
  • Random Allocation
  • Tissue Distribution
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Annexin A5
  • Antineoplastic Agents, Alkylating
  • Organotechnetium Compounds
  • Radiopharmaceuticals
  • technetium Tc 99m HYNIC annexin V
  • Cyclophosphamide